Prosecution Insights
Last updated: November 12, 2026
Application No. 18/895,915

COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF

Non-Final OA §DOUBLEPATENT
Filed
Sep 25, 2024
Priority
Feb 18, 2022 — provisional 63/311,621 +2 more
Examiner
SAMALA, JAGADISHWAR RAO
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Full-Life Technologies Hk Limited
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
543 granted / 799 resolved
+8.0% vs TC avg
Strong +56% interview lift
Without
With
+55.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
33 currently pending
Career history
829
Total Applications
across all art units

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status This Office action details a first action on the merits for the above referenced application No. Claims 102-137 are pending in this application. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 09/25/2024 was noted and the submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Drawings The drawings were received on 09/25/2024. These drawings are acknowledged. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 102-137 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 12,145,926 in view of Albert et al. (US 6,183,721). Although the conflicting claims are not identical, the Examiner finds that a person having ordinary skill in the art would recognize that the claimed invention would unjustly extend the rights granted to U.S. Patents, because a hypothetical infringer of U.S Patent granted would necessarily be an infringer of the claimed invention. The patent recites a compound of the formula: PNG media_image1.png 324 435 media_image1.png Greyscale , or a pharmaceutically acceptable salt or solvate thereof. And instant claims are drawn to a radionuclide complex comprising a compound of Formula: PNG media_image1.png 324 435 media_image1.png Greyscale , or a pharmaceutically acceptable salt or solvate thereof. The only difference between the instant claims and the patent recited claims is the chelator (DOTA) is complexed with one or more radionuclides. Albert teaches chelated peptides, complexes thereof, pharmaceutical compositions comprising a compound of formula I or a compound of formula I complexed with a radionuclide and their use as radiopharmaceuticals (abstract). PNG media_image2.png 230 462 media_image2.png Greyscale Albert discloses that the complexation with the radionuclide may be performed at room temperature in accordance with methods known in the art, e.g., by reacting an uncomplexed compound with a salt yielding the desired radionuclide (Col. 2 line 63+). The radionuclide includes α- or ß- emitting nuclide e.g., 90Y, ¹⁶¹Tb, ¹⁶⁹Er, ¹⁵³Sm, ¹⁷⁷Lu, ¹⁶⁶Dy, ¹⁶⁶Ho or ¹⁷⁵Yb (Col. line 22-25). It would have been obvious to one of ordinary skill in the art to label DOTA peptide conjugates with radiometal ions such as 90Y, ¹⁶¹Tb, ¹⁶⁹Er, ¹⁵³Sm, ¹⁷⁷Lu, ¹⁶⁶Dy, ¹⁶⁶Ho or ¹⁷⁵Yb, to high specific activity by optimizing the conditions such as pH, temperature, ligand to metal ratio and choice of buffer. Thus, 161Tb chelate as claimed are considered to be obvious variants of cited chelates because Albert teaches that complexation with a radionuclide, exhibit pharmaceutical activity and because Tb forms thermodynamically and kinetically stable associates with macrocyclic chelator. Accordingly, claims are overlapping in scope and are obvious variants of one another. It would have been obvious to the person of ordinary skill in the art at the time the invention was made to incorporate α- or ß- emitting nuclide e.g., 90Y, 140La, 161Tb, 169Er, 153Sm, 177Lu, 166Dy, 166Ho or 175Yb into patents as taught by Albert. The person of ordinary skill in the art would have been motivated to make those modifications, because Albert teaches that compound of formula I, when complexed with a radionuclide, exhibit pharmaceutical activity and are therefore useful as a radiopharmaceutical for the in vivo treatment of tumors and metastases as indicated by standard tests (Col 3 line 15-20) and reasonably would have expected success because the compounds complexed with radionuclide have an antiproliferative effect on tumor cells bearing somatostatin receptors. Accordingly, U.S. Patent No. 12,145,926 renders the instant claims obvious absent a showing of unpredictability or comparative evidence suggesting otherwise. Conclusion No claims are allowed at this time. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAGADISHWAR RAO SAMALA whose telephone number is (571)272-9525. The examiner can normally be reached Monday-Friday 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Hartley G Michael can be reached at 571 272 0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.R.S/Examiner, Art Unit 1618 /Michael G. Hartley/Supervisory Patent Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Sep 25, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779055
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF
4y 10m to grant Granted Nov 03, 2026
Patent 12780844
FLUORESCENT DYE FOR PROTEIN OR NUCLEIC ACID LABELLING
3y 6m to grant Granted Nov 03, 2026
Patent 12773453
FLUORESCENT SYSTEMS FOR BIOLOGICAL IMAGING AND USES THEREOF
4y 9m to grant Granted Oct 27, 2026
Patent 12763228
COPPER-64 COMPOSITIONS AND FORMULATIONS
1y 3m to grant Granted Oct 13, 2026
Patent 12752008
COMPOSITION CONTAINING BUFFER
2y 7m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+55.7%)
Low
PTA Risk
Based on 799 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month